Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition.

Biochemical and biophysical research communications - 29 Jan 2017

Zhu Yuanjun, Lin Yuan, Liu Xiaoyan, Hu Wenhui, Wang Yinye

Abstract excerpt

Ancylostoma caninum anticoagulant peptide 5 (AcAP5) is a potent inhibitor for coagulation factor Xa (FXa). Previous studies show that AcAP5 binds to FXa at the active site, and/or the exosite. The active site-binding contributes to direct blocking of FXa catalytic activity, but the effect of exosite-binding and the underlying mechanism remain unknown. To investigate whether and how the exosite-binding affects FXa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Binding Sites
Share to Catalytic Domain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Factor Xa

Share to Helminth Proteins

Share to Molecular Dynamics Simulation

Share to Rabbits

Source

Identifiers

PMID: 28007598
DOI: 10.1016/j.bbrc.2016.12.116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition.PMID 28007598Read ↗

Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions.Semantic proximity Read ↗

An RNA aptamer exploits exosite-dependent allostery to achieve specific inhibition of coagulation factor IXaSemantic proximity Read ↗

Targeting the S2 Subsite Enables the Structure-Based Discovery of Novel Highly Selective Factor XIa InhibitorsSemantic proximity Read ↗

P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor.Semantic proximity Read ↗

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivoSemantic proximity Read ↗

Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.Semantic proximity Read ↗

The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.Semantic proximity Read ↗

The plasma Factor XIII heterotetrameric complex structure: unexpected unequal pairing within a symmetric complexSemantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Targeting the GPIbα binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects.Semantic proximity Read ↗

Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2.Semantic proximity Read ↗

Heparin modulates the 99-loop of factor IXa: effects on reactivity with isolated Kunitz-type inhibitor domains.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.